Statins and risk of type 2 diabetes: mechanism and clinical implications
Statins are widely used to prevent cardiovascular disease events. Cardiovascular diseases and type 2 diabetes are tightly connected since type 2 diabetes is a major risk factor for cardiovascular diseases. Additionally, cardiovascular diseases often precede the development of type 2 diabetes. These...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1239335/full |
| _version_ | 1797680777965600768 |
|---|---|
| author | Markku Laakso Markku Laakso Lilian Fernandes Silva |
| author_facet | Markku Laakso Markku Laakso Lilian Fernandes Silva |
| author_sort | Markku Laakso |
| collection | DOAJ |
| description | Statins are widely used to prevent cardiovascular disease events. Cardiovascular diseases and type 2 diabetes are tightly connected since type 2 diabetes is a major risk factor for cardiovascular diseases. Additionally, cardiovascular diseases often precede the development of type 2 diabetes. These two diseases have common genetic and environmental antecedents. Statins are effective in the lowering of cardiovascular disease events. However, they have also important side effects, including an increased risk of type 2 diabetes. The first study reporting an association of statin treatment with the risk of type 2 diabetes was the WOSCOPS trial (West of Scotland Coronary Prevention Study) in 2001. Other primary and secondary cardiovascular disease prevention studies as well as population-based studies have confirmed original findings. The purpose of our review is to examine and summarize the most important findings of these studies as well as to describe the mechanisms how statins increase the risk of type 2 diabetes. |
| first_indexed | 2024-03-11T23:35:13Z |
| format | Article |
| id | doaj.art-a85dd0f8f2f14616b409beb5e67fc35f |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-11T23:35:13Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-a85dd0f8f2f14616b409beb5e67fc35f2023-09-20T04:48:43ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-09-011410.3389/fendo.2023.12393351239335Statins and risk of type 2 diabetes: mechanism and clinical implicationsMarkku Laakso0Markku Laakso1Lilian Fernandes Silva2Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, FinlandKuopio University Hospital, Kuopio, FinlandInstitute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, FinlandStatins are widely used to prevent cardiovascular disease events. Cardiovascular diseases and type 2 diabetes are tightly connected since type 2 diabetes is a major risk factor for cardiovascular diseases. Additionally, cardiovascular diseases often precede the development of type 2 diabetes. These two diseases have common genetic and environmental antecedents. Statins are effective in the lowering of cardiovascular disease events. However, they have also important side effects, including an increased risk of type 2 diabetes. The first study reporting an association of statin treatment with the risk of type 2 diabetes was the WOSCOPS trial (West of Scotland Coronary Prevention Study) in 2001. Other primary and secondary cardiovascular disease prevention studies as well as population-based studies have confirmed original findings. The purpose of our review is to examine and summarize the most important findings of these studies as well as to describe the mechanisms how statins increase the risk of type 2 diabetes.https://www.frontiersin.org/articles/10.3389/fendo.2023.1239335/fullstatintype 2 diabetesglucoseinsulin secretioninsulin resistance |
| spellingShingle | Markku Laakso Markku Laakso Lilian Fernandes Silva Statins and risk of type 2 diabetes: mechanism and clinical implications Frontiers in Endocrinology statin type 2 diabetes glucose insulin secretion insulin resistance |
| title | Statins and risk of type 2 diabetes: mechanism and clinical implications |
| title_full | Statins and risk of type 2 diabetes: mechanism and clinical implications |
| title_fullStr | Statins and risk of type 2 diabetes: mechanism and clinical implications |
| title_full_unstemmed | Statins and risk of type 2 diabetes: mechanism and clinical implications |
| title_short | Statins and risk of type 2 diabetes: mechanism and clinical implications |
| title_sort | statins and risk of type 2 diabetes mechanism and clinical implications |
| topic | statin type 2 diabetes glucose insulin secretion insulin resistance |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1239335/full |
| work_keys_str_mv | AT markkulaakso statinsandriskoftype2diabetesmechanismandclinicalimplications AT markkulaakso statinsandriskoftype2diabetesmechanismandclinicalimplications AT lilianfernandessilva statinsandriskoftype2diabetesmechanismandclinicalimplications |